

Diagnostics Advisory Committee Interests Register

Topic: Transperineal biopsy for diagnosing prostate cancer

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mark Kroese	Chair	-	(Nothing to add to my annual disclosure)	-	-	-	
Alasdair Taylor	Standing committee member	None	-	-	-	-	
Alexandria Moseley	Standing committee member	None	-	-	-	-	
Brian Shine	Standing committee member	None	-	-	-	-	
Brendan Meyer	Standing committee member	None	-	-	-	-	
Diane Davies	Standing committee member	None	-	-	-	-	
Jim Gray	Standing committee member	None	-	-	-	-	
John Cairns	Standing committee member	Financial	Advising Astellas on economic evaluation of Roxadustat Advising Takeda on economic evaluation of maribavir	Nov 2020 August 2021	Dec 2021 Dec 2021	May 2021 August 2021	<i>Declare and participate, Chair 06122021</i>
Joy Allen	Standing committee member	Financial	Employee of Roche Diagnostics UK & Ireland	August 2021	March 2022		<i>Declare and participate, Chair 15032022</i>
Joy Allen	Standing committee member		My employer, Roche manufacture a PSA test to aid in screening for prostate cancer		March 2022		<i>Declare and participate, Chair 21032022</i>
Joy Allen	Standing committee member	Non-financial personal and professional interests	Guest Researcher status, Newcastle University for collaborations with the NIHR In Vitro Diagnostics Co-operative	August 2021	March 2022		<i>Declare and participate, Chair 15032022</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			on diagnostic test evaluation methodology				
Joy Allen	Standing committee member	Non-financial personal and professional interests	I am co-author on a number of publications describing evaluation of diagnostic test evaluations, some of which include commercially supplied tests. All evaluations which I undertook during my time at the NIHR Diagnostic Evidence Co-operative and more recently at the Newcastle In Vitro Diagnostics Co-operative were independent investigator initiated studies.	September 2014	March 2022	August 2021	<i>Declare and participate, Chair 15032022</i>
Joy Allen	Standing committee member	Non-financial personal and professional interests	<p>Range of funding as co-applicant or PI in my previous roles:</p> <p>Co-applicant on NIHR i4i Connect Award: 'GlycoScore: Superior prostate cancer diagnosis using a simple blood test'. Role: Lead on the care pathway analysis and early economic modelling studies. Feb 2021 – April 2022. Award Value: £150K</p> <p>Co-Investigator on UKRI funded 'COVID-19 National Diagnostic Research and Evaluation platform (CONDOR)'. This study is on the Urgent Public Health Portfolio. Role: Lead the Care Pathway Analysis workstream. May 2020- June 2021. Award Value: £1.3m</p> <p>Co-applicant on NIHR Product Development Award 'Development of RxSelex: A microbiome-based predictive diagnostic of IBD biologics treatment outcome'. Role: Lead on</p>	May 2017	March 2022	August 2021	<i>Declare and participate, Chair 15032022</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			<p>barriers to adoptions studies. . Jan 2019 – Aug 2021 Award value: £1.2m</p> <p>Co-applicant on MRC CIC funded 'GlycoScore: Validation of a non-invasive diagnostic test to distinguish benign and aggressive prostate cancer' Role: Lead Early feasibility pathway studies. Jan 2020 – Sept 2020. Award Value: £80K</p> <p>Co-applicant on HTA commissioned call entitled 'Primary care management of lower urinary tract symptoms in men: Development and validation of a diagnostic and decision-making aid (The PriMUS Study)'. Role: Lead in the development of the prototype decision aid and mathematically modelling the effect of the tool on secondary care referral rates. May 2017 – April 2020. Award value: ~£1.56m</p> <p>Co-applicant on HTA commissioned call entitled 'Antifungal stewardship opportunities with rapid tests: The A-Stop Study'. Role: Lead on novel statistical analyses to overcome imperfect reference standard. April 2017 – March 2021. Award value: ~£1.5m</p>				
Karen Sennett	Standing committee member	None	-	-	-	-	
Keith Abrams	Standing committee member	Financial	May 2019 to date - Partner & Director, Visible Analytics Limited - a HTA Consultancy				<i>Declare and participate, Chair 21 March 2022</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			company, but I have not been involved in any projects which involve a diagnostic technology.				
Keith Abrams	Standing committee member	Non-financial professional and personal interests	<p>£750K MRC/NIHR Methods Research Programme January 2019 (3.5 years). Dias S, Abrams KR, et al: Inferring relative treatment effects from combined randomised and observational data.</p> <p>£450K MRC/NIHR Methods Research Programme Oct 2021 (3 years). S Bujkiewicz, RK Owen, KR Abrams, et al: HCD: Novel approaches of multi-parameter evidence synthesis and decision modelling for efficient evaluation of diagnostic health technologies in HTA decision making with use of electronic health records</p>	<p>Jan 2019</p> <p>Oct 2021</p>	March 2022		<i>Declare and participate, Chair 21 March 2022</i>
Liz Adair	Standing committee member	None	-	-	-	-	-
Matt Stevenson	Standing committee member	None	-	-	-	-	
Michael Messenger	Standing committee member	Financial	PinPoint DataScience Ltd - I am a co-inventor of the PinPoint Cancer Test, a machine learning based blood test for the diagnosis of cancer, including prostate cancer. Although I have no shares or other interests in PinPoint DataScience Ltd, I may benefit personally from this technology	24/3/2016	Nov 2021	Ongoing	<i>Declare and participate, Chair 24 November 2021</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			via a commercialisation agreement they hold with the University of Leeds.				
Michael Messenger	Standing committee member	Non-financial professional and personal interests	Myriad Genetics - I have previously received funding from Myriad Genetics Inc to evaluate their PROLARIS test for prostate cancer prognosis.	08/03/2017	Nov 2021	01/10/2020	<i>Declare and participate, Chair 24 November 2021</i>
Neil Hawkins	Standing committee member	Financial	A company that I am a director of has provided consultancy services regarding health technology assessment issues to a company (not amongst the companies listed) developing a potential treatments for advanced prostate cancer. No consultancy was provided or requested regarding diagnostic technologies.	May 2020	7 Nov 2021	Ongoing	<i>Declare and participate, Chair 24 November 2021</i>
Patrick McGinley	Standing committee member	Financial	Faculty Member of MTech Access. Honorarium received for advising on NHS Finance flows. Began April 2020 and is ongoing.	April 2020	7 Dec 2021	Ongoing	
Patrick McGinley	Standing committee member	Non-financial professional and personal interests	Member of Strategic Council for the All Party Parliamentary Group on Obesity started October 2019 and is ongoing	October 2019	7 Dec 2021	Ongoing	
Patrick McGinley	Standing committee member	Non-financial professional and personal interests	Hon Treasurer for Association for Study of Obesity (ASO) Began October 2020 and is ongoing	October 2020	7 Dec 2021	Ongoing	
Radha Ramachandran	Standing committee member	None	-	-	-	-	
Rebecca Allcock	Standing committee member	None	-	-	-	-	

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Shelley Rahman Haley	Standing committee member	None	-	-	-	-	
Sam Creavin	Standing committee member	None	-	-	-	-	